Latest news and press releases about enGene Holdings Inc. (ENGN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid.
Price
| Price | $1.91 |
| Market Cap | $128M |
| Exchange | NASDAQ |
| Country | CA |
Valuation Ratios
| Price / Book | 0.58 |
| EV / EBITDA | -0.86 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -2.10% |
| Return on Invested Capital | -1.61% |
| Return on Assets | -1.70% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACIU · ALT · AMRN · ANNX · ANRO · CLLS · DBVT
Explore sector: Healthcare · Biotechnology
More sections of ENGN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks